MOG35-55 CAS:149635-73-4

MOG35-55 peptide is primarily used in research to induce experimental autoimmune encephalomyelitis (EAE) in animal models. EAE serves as a valuable tool for studying the pathogenesis and potential treatments of multiple sclerosis (MS), a chronic autoimmune disorder characterized by demyelination of nerve fibers in the central nervous system (CNS). In EAE models, MOG35-55 peptide is administered to animals to trigger an immune response against myelin components, leading to inflammation and neurological symptoms resembling those seen in MS patients. This model allows researchers to investigate the mechanisms underlying autoimmune attacks on myelin and to test novel therapeutic strategies aimed at modulating the immune response and preventing neurodegeneration. Studies using MOG35-55 peptide have provided insights into the role of T cells and other immune cells in the progression of MS-like pathology. By manipulating the administration protocols or modifying the peptide sequence, researchers can explore different aspects of disease progression and evaluate the efficacy of potential treatments, such as immunomodulatory drugs or cell-based therapies. Furthermore, MOG35-55 peptide is used in preclinical studies to assess the safety and effectiveness of candidate MS treatments before advancing to clinical trials. This peptide model helps researchers screen potential therapies and refine treatment protocols based on their impact on disease severity, immune responses, and neuroprotection. Overall, MOG35-55 peptide remains a critical tool in MS research, facilitating the development of new insights and therapeutic interventions aimed at improving outcomes for patients with this debilitating neurological condition.